Influenza neuraminidase as a vaccine antigen

Current Topics in Microbiology and Immunology

Volumn 386, Issue , 2014, Pages 275-299

  Eichelberger, Maryna C ^a   Wan, Hongquan ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; INFLUENZA VACCINE; VIRUS SIALIDASE; SIALIDASE;

ANTIGEN RECOGNITION; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG APPROVAL; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; IMMUNOGENICITY; INFLUENZA; INFLUENZA A (H3N2); INFLUENZA VACCINATION; NONHUMAN; PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; SURFACE PROPERTY; VIRION; VIRUS PARTICLE; ANIMAL; CHEMISTRY; ENZYMOLOGY; IMMUNOLOGY; MOUSE; ORTHOMYXOVIRUS; PHYSIOLOGY;

ANIMALS; HUMANS; INFLUENZA VACCINES; MICE; NEURAMINIDASE; ORTHOMYXOVIRIDAE;

EID: 84921524431     PISSN: 0070217X     EISSN: 21969965     Source Type: Book Series    
DOI: 10.1007/82_2014_398     Document Type: Article

References (98)

1. Air GM (2012) Influenza neuraminidase. Influenza Other Respir Viruses 6(4): 245-256. doi: 10. 1111/j. 1750-2659. 2011. 00304. x.
2. Air GM, Laver WG, Webster RG (1990) Mechanism of antigenic variation in an individual epitope on influenza virus N9 neuraminidase. J Virol 64(12): 5797-5803.
3. Aminoff D (1959) The determination of free sialic acid in the presence of the bound compound. Virology 7(3): 355-357.
4. Bodewes R, Kreijtz JH, Baas C, Geelhoed-Mieras MM, de Mutsert G, van Amerongen G, van den Brand JM, Fouchier RA, Osterhaus AD, Rimmelzwaan GF (2009a) Vaccination against human influenza A/H3N2 virus prevents the induction of heterosubtypic immunity against lethal infection with avian influenza A/H5N1 virus. PLoS ONE 4(5): e5538. doi: 10. 1371/journal. pone. 0005538.
5. Bodewes R, Kreijtz JH, Rimmelzwaan GF (2009b) Yearly influenza vaccinations: a double-edged sword? Lancet Infect Dis 9(12): 784-788. doi: 10. 1016/S1473-3099(09)70263-4.
6. Brett IC, Johansson BE (2006) Variation in the divalent cation requirements of influenza A virus N1 neuraminidases. J Biochem 139(3): 439-447. doi: 10. 1093/jb/mvj051.
7. Brown DM, Lee S, Garcia-Hernandez Mde L, Swain SL (2012) Multifunctional CD4 cells expressing gamma interferon and perforin mediate protection against lethal influenza virus infection. J Virol 86(12): 6792-6803. doi: 10. 1128/JVI. 07172-11.
8. Burmeister WP, Ruigrok RW, Cusack S (1992) The 2. 2 A resolution crystal structure of influenza B neuraminidase and its complex with sialic acid. EMBO J 11(1): 49-56.
9. Calder LJ, Wasilewski S, Berriman JA, Rosenthal PB (2010) Structural organization of a filamentous influenza A virus. Proc Natl Acad Sci USA 107(23): 10685-10690. doi: 10. 1073/pnas. 1002123107.
10. Carrat F, Lavenu A, Cauchemez S, Deleger S (2006) Repeated influenza vaccination of healthy children and adults: borrow now, pay later? Epidemiol Infect 134(1): 63-70. doi: 10. 1017/S0950268805005479.
11. Cate TR, Rayford Y, Nino D, Winokur P, Brady R, Belshe R, Chen W, Atmar RL, Couch RB (2010) A high dosage influenza vaccine induced significantly more neuraminidase antibody than standard vaccine among elderly subjects. Vaccine 28(9): 2076-2079.
12. Chen Z, Kim L, Subbarao K, Jin H (2012) The 2009 pandemic H1N1 virus induces antineuraminidase (NA) antibodies that cross-react with the NA of H5N1 viruses in ferrets. Vaccine 30(15): 2516-2522. doi: 10. 1016/j. vaccine. 2012. 01. 090.
13. Chong AK, Pegg MS, von Itzstein M (1991) Influenza virus sialidase: effect of calcium on steady-state kinetic parameters. Biochim Biophys Acta 1077(1): 65-71.
14. Clements ML, Betts RF, Tierney EL, Murphy BR (1986) Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 24(1): 157-160.
15. Colacino JM, Chirgadze NY, Garman E, Murti KG, Loncharich RJ, Baxter AJ, Staschke KA, Laver WG (1997) A single sequence change destabilizes the influenza virus neuraminidase tetramer. Virology 236(1): 66-75. doi: 10. 1006/viro. 1997. 8709.
16. Couch RB, Atmar RL, Franco LM, Quarles JM, Wells J, Arden N, Nino D, Belmont JW (2013) Antibody correlates and predictors of immunity to naturally occurring influenza in humans and the importance of antibody to the neuraminidase. J Infect Dis 207(6): 974-981.
17. Couch RB, Atmar RL, Keitel WA, Quarles JM, Wells J, Arden N, Nino D (2012) Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. Vaccine 31(1): 190-195.
18. Couch RB, Kasel JA, Gerin JL, Schulman JL, Kilbourne ED (1974) Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 129(4): 411-420.
19. Couch RB, Winokur P, Brady R, Belshe R, Chen WH, Cate TR, Sigurdardottir B, Hoeper A, Graham IL, Edelman R, He F, Nino D, Capellan J, Ruben FL (2007) Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 25(44): 7656-7663. doi: 10. 1016/j. vaccine. 2007. 08. 042.
20. De Groot AS, Ardito M, McClaine EM, Moise L, Martin WD (2009) Immunoinformatic comparison of T-cell epitopes contained in novel swine-origin influenza A (H1N1) virus with epitopes in 2008-2009 conventional influenza vaccine. Vaccine 27(42): 5740-5747. doi: 10. 1016/j. vaccine. 2009. 07. 040.
21. Dowdle WR (1972) Influenza anti-neuraminidase: the second best antibody. N Engl J Med 286(25): 1360-1361. doi: 10. 1056/NEJM197206222862511.
22. Dowdle WR, Coleman MT, Mostow SR, Kaye HS, Schoenbaum SC (1973) Inactivated influenza vaccines. 2. Laboratory indices of protection. Postgrad Med J 49(569): 159-163.
23. Doyle TM, Hashem AM, Li C, Van Domselaar G, Larocque L, Wang J, Smith D, Cyr T, Farnsworth A, He R, Hurt AC, Brown EG, Li X (2013) Universal anti-neuraminidase antibody inhibiting all influenza A subtypes. Antiviral Res 100(2): 567-574. doi: 10. 1016/j. antiviral. 2013. 09. 018.
24. Easterbrook JD, Schwartzman LM, Gao J, Kash JC, Morens DM, Couzens L, Wan H, Eichelberger MC, Taubenberger JK (2012) Protection against a lethal H5N1 influenza challenge by intranasal immunization with virus-like particles containing 2009 pandemic H1N1 neuraminidase in mice. Virology 432(1): 39-44. doi: 10. 1016/j. virol. 2012. 06. 003.
25. Fazekas de St G, Webster RG (1966) Disquisitions of original antigenic sin. I. evidence in man. J Exp Med 124(3): 331-345.
26. Forrest BD, Pride MW, Dunning AJ, Capeding MR, Chotpitayasunondh T, Tam JS, Rappaport R, Eldridge JH, Gruber WC (2008) Correlation of cellular immune responses with protection against culture-confirmed influenza virus in young children. Clin Vaccine Immunol 15(7): 1042-1053. doi: 10. 1128/CVI. 00397-07.
27. Fries LF, Smith GE, Glenn GM (2013) A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 369(26): 2564-2566. doi: 10. 1056/NEJMc1313186.
28. Fritz R, Sabarth N, Kiermayr S, Hohenadl C, Howard MK, Ilk R, Kistner O, Ehrlich HJ, Barrett PN, Kreil TR (2012) A vero cell-derived whole-virus H5N1 vaccine effectively induces neuraminidase-inhibiting antibodies. J Infect Dis 205(1): 28-34. doi: 10. 1093/infdis/jir711.
29. Gerentes L, Kessler N, Aymard M (1999) Difficulties in standardizing the neuraminidase content of influenza vaccines. Dev Biol Stand 98: 189-196; discussion 197.
30. Getie-Kebtie M, Sultana I, Eichelberger M, Alterman M (2013) Label-free mass spectrometrybased quantification of hemagglutinin and neuraminidase in influenza virus preparations and vaccines. Influenza Other Respir Viruses 7(4): 521-530. doi: 10. 1111/irv. 12001.
31. Gillim-Ross L, Subbarao K (2007) Can immunity induced by the human influenza virus N1 neuraminidase provide some protection from avian influenza H5N1 viruses? PLoS medicine 4(2): e91. doi: 10. 1371/journal. pmed. 0040091.
32. Gorse GJ, Falsey AR, Fling JA, Poling TL, Strout CB, Tsang PH (2013) Intradermallyadministered influenza virus vaccine is safe and immunogenic in healthy adults 18-64 years of age. Vaccine 31(19): 2358-2365. doi: 10. 1016/j. vaccine. 2013. 03. 008.
33. Gulati U, Hwang CC, Venkatramani L, Gulati S, Stray SJ, Lee JT, Laver WG, Bochkarev A, Zlotnick A, Air GM (2002) Antibody epitopes on the neuraminidase of a recent H3N2 influenza virus (A/Memphis/31/98). J Virol 76(23): 12274-12280.
34. Hassantoufighi A, Zhang H, Sandbulte M, Gao J, Manischewitz J, King L, Golding H, Straight TM, Eichelberger MC (2010) A practical influenza neutralization assay to simultaneously quantify hemagglutinin and neuraminidase-inhibiting antibody responses. Vaccine 28(3): 790-797.
35. Hensley SE, Das SR, Gibbs JS, Bailey AL, Schmidt LM, Bennink JR, Yewdell JW (2011) Influenza A virus hemagglutinin antibody escape promotes neuraminidase antigenic variation and drug resistance. PLoS ONE 6(2): e15190. doi: 10. 1371/journal. pone. 0015190.
36. Jameson J, Cruz J, Ennis FA (1998) Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol 72(11): 8682-8689.
37. Johansson BE, Brett IC (2003) Variation in the divalent cation requirements of influenza a virus N2 neuraminidases. J Biochem 134(3): 345-352.
38. Johansson BE, Bucher DJ, Kilbourne ED (1989) Purified influenza virus hemagglutinin and neuraminidase are equivalent in stimulation of antibody response but induce contrasting types of immunity to infection. J Virol 63(3): 1239-1246.
39. Johansson BE, Cox MM (2011) Influenza viral neuraminidase: the forgotten antigen. Expert Rev Vaccines 10(12): 1683-1695. doi: 10. 1586/erv. 11. 130.
40. Johansson BE, Kilbourne ED (1993) Dissociation of influenza virus hemagglutinin and neuraminidase eliminates their intravirionic antigenic competition. J Virol 67(10): 5721-5723.
41. Johansson BE, Matthews JT, Kilbourne ED (1998) Supplementation of conventional influenza A vaccine with purified viral neuraminidase results in a balanced and broadened immune response. Vaccine 16(9-10): 1009-1015.
42. Johansson BE, Moran TM, Bona CA, Popple SW, Kilbourne ED (1987) Immunologic response to influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. II. Sequential infection of mice simulates human experience. J Immunol 139(6): 2010-2014.
43. Khan MW, Gallagher M, Bucher D, Cerini CP, Kilbourne ED (1982) Detection of influenza virus neuraminidase-specific antibodies by an enzyme-linked immunosorbent assay. J Clin Microbiol 16(1): 115-122.
44. Khandaker G, Dierig A, Rashid H, King C, Heron L, Booy R (2011) Systematic review of clinical and epidemiological features of the pandemic influenza A (H1N1) 2009. Influenza Other Respir Viruses 5(3): 148-156. doi: 10. 1111/j. 1750-2659. 2011. 00199. x.
45. Khurana S, Chearwae W, Castellino F, Manischewitz J, King LR, Honorkiewicz A, Rock MT, Edwards KM, Del Giudice G, Rappuoli R, Golding H (2010) Vaccines with MF59 adjuvant expand the antibody repertoire to target protective sites of pandemic avian H5N1 influenza virus. Sci Transl Med 2(15): 15ra5. doi: 10. 1126/scitranslmed. 3000624.
46. Kilbourne ED (1972) Orthomyxoviruses and paramyxoviruses. In: Melnick JL (ed) International virology, 2nd edn. Karger, Basel, Switzerland, pp 121-137.
47. Kilbourne ED (1976) Comparative efficacy of neuraminidase-specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J Infect Dis 134(4): 384-394.
48. Kilbourne ED, Cerini CP, Khan MW, Mitchell JW Jr, Ogra PL (1987) Immunologic response to the influenza virus neuraminidase is influenced by prior experience with the associated viral hemagglutinin. I. Studies in human vaccinees. J Immunol 138(9): 3010-3013.
49. Kilbourne ED, Couch RB, Kasel JA, Keitel WA, Cate TR, Quarles JH, Grajower B, Pokorny BA, Johansson BE (1995) Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans. Vaccine 13(18): 1799-1803.
50. Kilbourne ED, Johansson BE, Grajower B (1990) Independent and disparate evolution in nature of influenza A virus hemagglutinin and neuraminidase glycoproteins. Proc Natl Acad Sci USA 87(2): 786-790.
51. Kilbourne ED, Laver WG, Schulman JL, Webster RG (1968) Antiviral activity of antiserum specific for an influenza virus neuraminidase. J Virol 2(4): 281-288.
52. Koel BF, Burke DF, Bestebroer TM, van der Vliet S, Zondag GC, Vervaet G, Skepner E, Lewis NS, Spronken MI, Russell CA, Eropkin MY, Hurt AC, Barr IG, de Jong JC, Rimmelzwaan GF, Osterhaus AD, Fouchier RA, Smith DJ (2013) Substitutions near the receptor binding site determine major antigenic change during influenza virus evolution. Science 342(6161): 976-979. doi: 10. 1126/science. 1244730.
53. Lakdawala SS, Lamirande EW, Suguitan AL Jr, Wang W, Santos CP, Vogel L, Matsuoka Y, Lindsley WG, Jin H, Subbarao K (2011) Eurasian-origin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus. PLoS Pathog 7(12): e1002443. doi: 10. 1371/journal. ppat. 1002443.
54. Lambre CR, Terzidis H, Greffard A, Webster RG (1990) Measurement of anti-influenza neuraminidase antibody using a peroxidase-linked lectin and microtitre plates coated with natural substrates. J Immunol Methods 135(1-2): 49-57.
55. Lentz MR, Air GM, Laver WG, Webster RG (1984) Sequence of the neuraminidase gene of influenza virus A/Tokyo/3/67 and previously uncharacterized monoclonal variants. Virology 135(1): 257-265.
56. Li Q, Qi J, Zhang W, Vavricka CJ, Shi Y, Wei J, Feng E, Shen J, Chen J, Liu D, He J, Yan J, Liu H, Jiang H, Teng M, Li X, Gao GF (2010) The 2009 pandemic H1N1 neuraminidase N1 lacks the 150-cavity in its active site. Nat Struct Mol Biol 17(10): 1266-1268. doi: 10. 1038/nsmb. 1909.
57. Li Q, Sun X, Li Z, Liu Y, Vavricka CJ, Qi J, Gao GF (2012) Structural and functional characterization of neuraminidase-like molecule N10 derived from bat influenza A virus. Proc Natl Acad Sci USA 109(46): 18897-18902. doi: 10. 1073/pnas. 1211037109.
58. Malby RL, Tulip WR, Harley VR, McKimm-Breschkin JL, Laver WG, Webster RG, Colman PM (1994) The structure of a complex between the NC10 antibody and influenza virus neuraminidase and comparison with the overlapping binding site of the NC41 antibody. Structure 2(8): 733-746.
59. Marcelin G, Bland HM, Negovetich NJ, Sandbulte MR, Ellebedy AH, Webb AD, Griffin YS, DeBeauchamp JL, McElhaney JE, Webby RJ (2010) Inactivated seasonal influenza vaccines increase serum antibodies to the neuraminidase of pandemic influenza A(H1N1) 2009 virus in an age-dependent manner. J Infect Dis 202(11): 1634-1638. doi: 10. 1086/657084.
60. Marcelin G, DuBois R, Rubrum A, Russell CJ, McElhaney JE, Webby RJ (2011) A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus. PLoS ONE 6(10): e26335. doi: 10. 1371/journal. pone. 0026335.
61. Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD (2004) Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium. J Virol 78(22): 12665-12667. doi: 10. 1128/JVI. 78. 22. 12665-12667. 2004.
62. McKinstry KK, Strutt TM, Kuang Y, Brown DM, Sell S, Dutton RW, Swain SL (2012) Memory CD4+ T cells protect against influenza through multiple synergizing mechanisms. J Clin Investig 122(8): 2847-2856. doi: 10. 1172/JCI63689.
63. Moise L, Tassone R, Latimer H, Terry F, Levitz L, Haran JP, Ross TM, Boyle CM, Martin WD, De Groot AS (2013) Immunization with cross-conserved H1N1 influenza CD4 T-cell epitopes lowers viral burden in HLA DR3 transgenic mice. Hum Vaccines Immunotherapeutics 9(10): 2060-2068.
64. Monto AS, Kendal AP (1973) Effect of neuraminidase antibody on Hong Kong influenza. Lancet 1(7804): 623-625.
65. Mostow SR, Schoenbaum SC, Dowdle WR, Coleman MT, Kaye HS (1969) Studies with inactivated influenza vaccines purified by zonal centrifugation. 1. Adverse reactions and serological responses. Bull World Health Organ 41(3): 525-530.
66. Murphy BR, Kasel JA, Chanock RM (1972) Association of serum anti-neuraminidase antibody with resistance to influenza in man. N Engl J Med 286(25): 1329-1332. doi: 10. 1056/NEJM197206222862502.
67. Nuss JM, Whitaker PB, Air GM (1993) Identification of critical contact residues in the NC41 epitope of a subtype N9 influenza virus neuraminidase. Proteins 15(2): 121-132. doi: 10. 1002/prot. 340150204.
68. Ogra PL, Chow T, Beutner KR, Rubi E, Strussenberg J, DeMello S, Rizzone C (1977) Clinical and immunologic evaluation of neuraminidase-specific influenza A virus vaccine in humans. J Infect Dis 135(4): 499-506.
69. Oh S, Eichelberger MC (1999) Influenza virus neuraminidase alters allogeneic T cell proliferation. Virology 264(2): 427-435. doi: 10. 1006/viro. 1999. 0019.
70. Oh S, Eichelberger MC (2000) Polarization of allogeneic T-cell responses by influenza virusinfected dendritic cells. J Virol 74(17): 7738-7744.
71. Ohuchi M, Asaoka N, Sakai T, Ohuchi R (2006) Roles of neuraminidase in the initial stage of influenza virus infection. Microbes Infect/Institut Pasteur 8(5): 1287-1293. doi: 10. 1016/j. micinf. 2005. 12. 008.
72. Palese P, Tobita K, Ueda M, Compans RW (1974) Characterization of temperature sensitive influenza virus mutants defective in neuraminidase. Virology 61(2): 397-410.
73. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, Houser KV, Pearce MB, Pappas C, Tumpey TM, Epstein SL (2010) Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS ONE 5(10): e13162. doi: 10. 1371/journal. pone. 0013162.
74. Quan FS, Kim MC, Lee BJ, Song JM, Compans RW, Kang SM (2012) Influenza M1 VLPs containing neuraminidase induce heterosubtypic cross-protection. Virology 430(2): 127-135. doi: 10. 1016/j. virol. 2012. 05. 006.
75. Russell RJ, Haire LF, Stevens DJ, Collins PJ, Lin YP, Blackburn GM, Hay AJ, Gamblin SJ, Skehel JJ (2006) The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design. Nature 443(7107): 45-49. doi: 10. 1038/nature05114.
76. Saito T, Taylor G, Laver WG, Kawaoka Y, Webster RG (1994) Antigenicity of the N8 influenza A virus neuraminidase: existence of an epitope at the subunit interface of the neuraminidase. J Virol 68(3): 1790-1796.
77. Saito T, Taylor G, Webster RG (1995) Steps in maturation of influenza A virus neuraminidase. J Virol 69(8): 5011-5017.
78. Sandbulte MR, Gao J, Straight TM, Eichelberger MC (2009) A miniaturized assay for influenza neuraminidase-inhibiting antibodies utilizing reverse genetics-derived antigens. Influenza Other Respir Viruses 3(5): 233-240.
79. Sandbulte MR, Jimenez GS, Boon AC, Smith LR, Treanor JJ, Webby RJ (2007) Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4(2): e59. doi: 10. 1371/journal. pmed. 0040059.
80. Sandbulte MR, Westgeest KB, Gao J, Xu X, Klimov AI, Russell CA, Burke DF, Smith DJ, Fouchier RA, Eichelberger MC (2011) Discordant antigenic drift of neuraminidase and hemagglutinin in H1N1 and H3N2 influenza viruses. Proc Natl Acad Sci USA 108(51): 20748-20753.
81. Schoenbaum SC, Mostow SR, Dowdle WR, Coleman MT, Kaye HS (1969) Studies with inactivated influenza vaccines purified by zonal centrifugation. 2. Efficacy. Bull World Health Organ 41(3): 531-535.
82. Schulman JL, Khakpour M, Kilbourne ED (1968) Protective effects of specific immunity to viral neuraminidase on influenza virus infection of mice. J Virol 2(8): 778-786.
83. Sultana I, Gao J, Markoff L, Eichelberger MC (2011) Influenza neuraminidase-inhibiting antibodies are induced in the presence of zanamivir. Vaccine 29(14): 2601-2606. doi: 10. 1016/j. vaccine. 2011. 01. 047.
84. Tulip WR, Varghese JN, Baker AT, van Donkelaar A, Laver WG, Webster RG, Colman PM (1991) Refined atomic structures of N9 subtype influenza virus neuraminidase and escape mutants. J Mol Biol 221(2): 487-497.
85. Tulip WR, Varghese JN, Laver WG, Webster RG, Colman PM (1992) Refined crystal structure of the influenza virus N9 neuraminidase-NC41 Fab complex. J Mol Biol 227(1): 122-148.
86. Varghese JN, Colman PM (1991) Three-dimensional structure of the neuraminidase of influenza virus A/Tokyo/3/67 at 2. 2 A resolution. J Mol Biol 221(2): 473-486.
87. Venkatramani L, Bochkareva E, Lee JT, Gulati U, Graeme Laver W, Bochkarev A, Air GM (2006) An epidemiologically significant epitope of a 1998 human influenza virus neuraminidase forms a highly hydrated interface in the NA-antibody complex. J Mol Biol 356(3): 651-663. doi: 10. 1016/j. jmb. 2005. 11. 061.
88. Wan H, Gao J, Xu K, Chen H, Couzens LK, Rivers KH, Easterbrook JD, Yang K, Zhong L, Rajabi M, Ye J, Sultana I, Wan XF, Liu X, Perez DR, Taubenberger JK, Eichelberger MC (2013) Molecular basis for broad neuraminidase immunity: conserved epitopes in seasonal and pandemic H1N1 as well as H5N1 influenza viruses. J Virol 87(16): 9290-9300. doi: 10. 1128/JVI. 01203-13.
89. Wang M, Qi J, Liu Y, Vavricka CJ, Wu Y, Li Q, Gao GF (2011) Influenza A virus N5 neuraminidase has an extended 150-cavity. J Virol 85(16): 8431-8435. doi: 10. 1128/JVI. 00638-11.
90. Warren L (1959) The thiobarbituric acid assay of sialic acids. J Biol Chem 234(8): 1971-1975.
91. Webster RG (1966) Original antigenic sin in ferrets: the response to sequential infections with influenza viruses. J Immunol 97(2): 177-183.
92. Webster RG, Air GM, Metzger DW, Colman PM, Varghese JN, Baker AT, Laver WG (1987) Antigenic structure and variation in an influenza virus N9 neuraminidase. J Virol 61(9): 2910-2916.
93. Webster RG, Brown LE, Laver WG (1984) Antigenic and biological characterization of influenza virus neuraminidase (N2) with monoclonal antibodies. Virology 135(1): 30-42.
94. Webster RG, Laver WG (1967) Preparation and properties of antibody directed specifically against the neuraminidase of influenza virus. J Immunol 99(1): 49-55.
95. Wu ZL, Ethen C, Hickey GE, Jiang W (2009) Active 1918 pandemic flu viral neuraminidase has distinct N-glycan profile and is resistant to trypsin digestion. Biochem Biophys Res Commun 379(3): 749-753. doi: 10. 1016/j. bbrc. 2008. 12. 139.
96. Xu X, Zhu X, Dwek RA, Stevens J, Wilson IA (2008) Structural characterization of the 1918 influenza virus H1N1 neuraminidase. J Virol 82(21): 10493-10501. doi: 10. 1128/JVI. 00959-08.
97. Yen HL, Liang CH, Wu CY, Forrest HL, Ferguson A, Choy KT, Jones J, Wong DD, Cheung PP, Hsu CH, Li OT, Yuen KM, Chan RW, Poon LL, Chan MC, Nicholls JM, Krauss S, Wong CH, Guan Y, Webster RG, Webby RJ, Peiris M (2011) Hemagglutinin-neuraminidase balance confers respiratory-droplet transmissibility of the pandemic H1N1 influenza virus in ferrets. Proc Natl Acad Sci USA 108(34): 14264-14269. doi: 10. 1073/pnas. 1111000108.
98. Zhu X, Yang H, Guo Z, Yu W, Carney PJ, Li Y, Chen LM, Paulson JC, Donis RO, Tong S, Stevens J, Wilson IA (2012) Crystal structures of two subtype N10 neuraminidase-like proteins from bat influenza A viruses reveal a diverged putative active site. Proc Natl Acad Sci USA 109(46): 18903-18908. doi: 10. 1073/pnas. 1212579109.